Thursday Jul 24
Synta Announces Ganetespib Into Phase 3 Extension Of Aml Li-1 Study;...
AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine , in newly diagnosed elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome who are not eligible for intensive chemotherapy.
Synta Pharmaceuticals advances ganetespib into Phase 3 extension of Aml Li-1
Synta Pharmaceuticals advances ganetespib into Phase 3 extension of AML LI-1 Synta Pharmaceuticals announced the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial.
Celator(R) Pharmaceuticals Provides Update on CPX-351 and Technology Platform at Analyst Day
"We are very excited to announce that we are broadening the application of the CombiPlex platform and expect to advance the technology to include molecularly targeted therapies in 2015," said .